<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Convatec Group Plc — News on 6ix</title>
<link>https://6ix.com/company/convatec-group-plc</link>
<description>Latest news and press releases for Convatec Group Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/convatec-group-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e28b78dffbe2df126e3b.webp</url>
<title>Convatec Group Plc</title>
<link>https://6ix.com/company/convatec-group-plc</link>
</image>
<item>
<title>Professor Constantin Coussios steps down</title>
<link>https://6ix.com/company/convatec-group-plc/news/professor-constantin-coussios-steps-down</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/professor-constantin-coussios-steps-down</guid>
<pubDate>Mon, 13 Apr 2026 11:00:00 GMT</pubDate>
<description>Convatec Group Plc announced that Professor Constantin Coussios OBE will step down as a Non-Executive Director effective April 30, 2026, to assume the role of Pro-Vice-Chancellor for Innovation at the University of Oxford. During his tenure since September 2020, Professor Coussios significantly contributed to transforming Convatec's research and development, accelerating new product development, and positioning the company for innovation-led growth, evidenced by a compressed internal new product</description>
</item>
<item>
<title>Capital Markets Day</title>
<link>https://6ix.com/company/convatec-group-plc/news/capital-markets-day-78</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/capital-markets-day-78</guid>
<pubDate>Thu, 09 Apr 2026 06:00:00 GMT</pubDate>
<description>Convatec Group PLC has unveiled its new 'Accelerate' strategy, building on the success of FISBE to drive sustainable and profitable growth, aiming for 6-8% annual organic revenue growth with specific targets for Advanced Wound Care, Ostomy Care, Continence Care, and double-digit growth in Infusion Care. The company also projects an adjusted operating margin of 24-26%, double-digit adjusted earnings per share growth, and double-digit free cash flow to equity growth. This strategy is supported by </description>
</item>
<item>
<title>Notice of AGM</title>
<link>https://6ix.com/company/convatec-group-plc/news/notice-of-agm-338</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/notice-of-agm-338</guid>
<pubDate>Tue, 17 Mar 2026 13:00:00 GMT</pubDate>
<description>Convatec Group Plc has announced its Annual General Meeting will be held on Thursday, 21 May 2026, at 14:00 UK time. The Notice of Annual General Meeting and Form of Proxy are being sent to shareholders and have been submitted to the National Storage Mechanism. The company, which reported revenues exceeding $2 billion in 2025, is a global medical products and technologies company focused on chronic condition management.
Disclaimer*</description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/convatec-group-plc/news/directorpdmr-shareholding-635</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/directorpdmr-shareholding-635</guid>
<pubDate>Tue, 17 Mar 2026 11:00:00 GMT</pubDate>
<description>Convatec Group Plc has announced the vesting of conditional share awards under its Long Term Incentive Plan and Deferred Bonus Plan for Chief Executive Officer Jonny Mason and Chief Financial Officer Fiona Ryder. On March 16, 2026, a total of 270,355 shares were retained by Jonny Mason and 14,272 by Fiona Ryder after sufficient shares were sold to cover income tax and National Insurance liabilities, with the transactions occurring at a share price of £2.344.
Disclaimer*</description>
</item>
<item>
<title>Convatec Introduces Co-Branded eakin freeseal® Ostomy Seal in North America, Expanding the ESENTA™ Family of Accessories</title>
<link>https://6ix.com/company/convatec-group-plc/news/convatec-introduces-co-branded-eakin-freesealr-ostomy-seal-in-north-america-expanding-the-esentatm-family-of-accessories</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/convatec-introduces-co-branded-eakin-freesealr-ostomy-seal-in-north-america-expanding-the-esentatm-family-of-accessories</guid>
<pubDate>Mon, 16 Mar 2026 14:03:00 GMT</pubDate>
<description>BOSTON & LONDON, March 16, 2026--Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, and Eakin Healthcare, a specialist provider of ostomy solutions, today announced the launch of eakin freeseal®, the thinnest ostomy seal used to help prevent leaks and protect the skin around a stoma. This new co-branded seal is part of the ESENTA™ family of accessories, available in the United States.</description>
</item>
<item>
<title>Publication of Annual Report</title>
<link>https://6ix.com/company/convatec-group-plc/news/publication-of-annual-report-12</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/publication-of-annual-report-12</guid>
<pubDate>Tue, 10 Mar 2026 13:00:00 GMT</pubDate>
<description>Convatec Group Plc has published its Annual Report and Accounts for the year ended 31 December 2025, which is now available on the company's website and will be posted to shareholders who have elected to receive paper communications. In accordance with regulatory requirements, a copy of the report has also been submitted to the Financial Conduct Authority and will be accessible via the National Storage Mechanism. The company, which reported revenues exceeding $2 billion in 2025, is a global medi</description>
</item>
<item>
<title>Convatec FY25 Results</title>
<link>https://6ix.com/company/convatec-group-plc/news/convatec-fy25-results</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/convatec-fy25-results</guid>
<pubDate>Tue, 24 Feb 2026 07:00:00 GMT</pubDate>
<description>Convatec Group PLC reported strong financial results for the year ended December 31, 2025, with revenue increasing by 6.5% to $2,439 million and adjusted diluted earnings per share growing by 16.0% to 17.6 cents. The company also announced an upgrade to its medium-term organic growth target to 6-8% from 2027, driven by a robust innovation pipeline. Adjusted operating profit rose by 12.1% to $544 million, with an improved adjusted operating margin of 22.3%. The company returned $300 million to sh</description>
</item>
<item>
<title>Convatec awarded Enterostomal Therapy Products agreements with Premier, Inc.</title>
<link>https://6ix.com/company/convatec-group-plc/news/convatec-awarded-enterostomal-therapy-products-agreements-with-premier-inc</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/convatec-awarded-enterostomal-therapy-products-agreements-with-premier-inc</guid>
<pubDate>Mon, 09 Feb 2026 14:00:00 GMT</pubDate>
<description>LONDON & BOSTON, February 09, 2026--Convatec, a global medical products and technologies company focused on solutions for the management of chronic conditions, has been awarded two group purchasing agreements in the Enterostomal Therapy Products category with Premier, Inc., effective April 1, 2026:</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/convatec-group-plc/news/holdings-in-company-709</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/holdings-in-company-709</guid>
<pubDate>Fri, 06 Feb 2026 11:00:00 GMT</pubDate>
<description>Black Creek Investment Management Inc. has increased its stake in Convatec Group PLC, crossing a notification threshold on February 3, 2026. The investment management company now holds 5.15% of the voting rights, up from a previous holding of 4.02%. This increase represents 100,676,401 voting rights, with 12,600,465 held directly and 88,075,936 held indirectly. The shares are beneficially owned by 14 separate funds and clients advised by Black Creek, with a portion managed by CI Investments Inc.</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/convatec-group-plc/news/total-voting-rights-148</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/total-voting-rights-148</guid>
<pubDate>Fri, 02 Jan 2026 11:00:00 GMT</pubDate>
<description>Convatec Group Plc has notified the market that as of December 31, 2025, its issued share capital consists of 2,049,789,559 ordinary shares, with 94,937,530 shares held in treasury, resulting in a total of 1,954,852,029 voting rights. This figure serves as the denominator for shareholders calculating their notification requirements under the FCA's Disclosure and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>Transaction in Own Shares</title>
<link>https://6ix.com/company/convatec-group-plc/news/transaction-in-own-shares-517</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/transaction-in-own-shares-517</guid>
<pubDate>Thu, 04 Dec 2025 07:00:00 GMT</pubDate>
<description>Convatec Group PLC has concluded its share buyback program of up to $300 million, having purchased 1,912,745 ordinary shares on December 3, 2025, at a volume-weighted average price of 230.19 pence per share, with the highest price paid being 233.00 pence and the lowest 227.20 pence. Following this transaction, the company now holds 94,937,530 shares in treasury, with 1,954,852,029 ordinary shares in issue, representing the total voting rights.
Disclaimer*</description>
</item>
<item>
<title>ConvaTec Group</title>
<link>https://6ix.com/company/convatec-group-plc/news/convatec-group</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/convatec-group</guid>
<pubDate>Tue, 18 Nov 2025 18:00:00 GMT</pubDate>
<description>FTSE Russell has announced changes to the investability weight of ConvaTec Group within the FTSE UK Index Series, effective from the start of trading on November 21, 2025. These adjustments follow updated shareholder information resulting from a secondary placing. ConvaTec Group will see its weighting altered in the FTSE 100 Index, FTSE 350 Index, FTSE All-Share Index, and FTSE 350 Lower Yield Index.
Disclaimer*</description>
</item>
<item>
<title>PRICED SECONDARY OFFERING IN CONVATEC GROUP PLC</title>
<link>https://6ix.com/company/convatec-group-plc/news/priced-secondary-offering-in-convatec-group-plc</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/priced-secondary-offering-in-convatec-group-plc</guid>
<pubDate>Tue, 18 Nov 2025 07:00:00 GMT</pubDate>
<description>Novo Holdings A/S has sold approximately 155 million ordinary shares in Convatec Group plc, representing 7.8% of its issued share capital, at a price of 227 pence per share, generating gross proceeds of £351 million. This secondary offering, managed by Goldman Sachs International and Morgan Stanley & Co. International Plc, will result in Novo Holdings fully exiting its position in Convatec, with settlement expected on November 20, 2025. Convatec itself will not receive any proceeds from this tra</description>
</item>
<item>
<title>PROPOSED SECONDARY OFFERING IN CONVATEC GROUP PLC</title>
<link>https://6ix.com/company/convatec-group-plc/news/proposed-secondary-offering-in-convatec-group-plc</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/proposed-secondary-offering-in-convatec-group-plc</guid>
<pubDate>Mon, 17 Nov 2025 16:57:00 GMT</pubDate>
<description>Novo Holdings A/S intends to sell approximately 155 million ordinary shares in Convatec Group plc, representing about 7.8% of the company's issued share capital, through a placing to institutional investors. This offering will be conducted via an accelerated bookbuilding process, and Novo Holdings will have no residual position in Convatec after the settlement of derivative transactions. Convatec Group plc is not selling any shares and will not receive any proceeds from this offering.
</description>
</item>
<item>
<title>Convatec Selects LTIMindtree for Strategic, AI-Powered SAP S/4HANA Transformation</title>
<link>https://6ix.com/company/convatec-group-plc/news/convatec-selects-ltimindtree-for-strategic-ai-powered-sap-s4hana-transformation-1</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/convatec-selects-ltimindtree-for-strategic-ai-powered-sap-s4hana-transformation-1</guid>
<pubDate>Mon, 17 Nov 2025 08:30:00 GMT</pubDate>
<description>LONDON & MUMBAI, India, November 17, 2025--LTIMindtree has announced its selection as a strategic partner by Convatec, for the implementation of SAP’s Digital Core – S/4HANA.</description>
</item>
<item>
<title>Trading update for 10 months ended 31 October 2025</title>
<link>https://6ix.com/company/convatec-group-plc/news/trading-update-for-10-months-ended-31-october-2025</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/trading-update-for-10-months-ended-31-october-2025</guid>
<pubDate>Thu, 13 Nov 2025 07:00:00 GMT</pubDate>
<description>Convatec Group PLC reported strong trading for the ten months ended October 31, 2025, with year-to-date organic revenue growth of 6.3% excluding InnovaMatrix®, and 5.0% including it, driven by new product launches across its Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care segments. The company is on track to meet its full-year 2025 financial targets, expecting an adjusted operating profit margin of 22.0-22.5% and double-digit adjusted EPS growth, with cash conversion around </description>
</item>
<item>
<title>CEO and CFO appointments</title>
<link>https://6ix.com/company/convatec-group-plc/news/ceo-and-cfo-appointments</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/ceo-and-cfo-appointments</guid>
<pubDate>Thu, 06 Nov 2025 07:00:00 GMT</pubDate>
<description>CEO and CFO appointments.</description>
</item>
<item>
<title>Convatec announces Karim Bitar has passed away</title>
<link>https://6ix.com/company/convatec-group-plc/news/convatec-announces-karim-bitar-has-passed-away</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/convatec-announces-karim-bitar-has-passed-away</guid>
<pubDate>Mon, 27 Oct 2025 13:00:00 GMT</pubDate>
<description>Convatec Group PLC announced the death of its CEO, Karim Bitar, on October 27, 2025, who had been on medical leave since August 4, 2025. The company stated that interim leadership arrangements remain in place, with a further announcement to be made in due course. Convatec's revenues in 2024 were over $2 billion.
Disclaimer*</description>
</item>
<item>
<title>Stigma, Not Condition, Is the Biggest Barrier for 1 in 3 People Living With Chronic Conditions, According to New Convatec Research</title>
<link>https://6ix.com/company/convatec-group-plc/news/stigma-not-condition-is-the-biggest-barrier-for-1-in-3-people-living-with-chronic-conditions-according-to-new-convatec-research</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/stigma-not-condition-is-the-biggest-barrier-for-1-in-3-people-living-with-chronic-conditions-according-to-new-convatec-research</guid>
<pubDate>Mon, 27 Oct 2025 12:00:00 GMT</pubDate>
<description>LONDON & BOSTON, October 27, 2025--Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, today announced the publication of a new report revealing that millions of people feel they need to hide their health conditions in plain sight. Perspectives on living with chronic conditions – research undertaken in the United States, United Kingdom, Germany, Italy, and Brazil – shows that while one in three people1 surveyed lives with a</description>
</item>
<item>
<title>Convatec announces pricing of Senior Notes</title>
<link>https://6ix.com/company/convatec-group-plc/news/convatec-announces-pricing-of-senior-notes</link>
<guid isPermaLink="true">https://6ix.com/company/convatec-group-plc/news/convatec-announces-pricing-of-senior-notes</guid>
<pubDate>Thu, 02 Oct 2025 10:00:00 GMT</pubDate>
<description>Convatec Group PLC has announced the pricing of $500 million aggregate principal amount of 5.300% senior notes due in 2035. The notes will bear interest at an annual rate of 5.300% and will be issued at 99.617% of their nominal value. The issuance and settlement are expected on October 8, 2025, contingent on standard closing conditions. The company plans to use the proceeds from this offering to refinance existing debt, including fully prepaying the outstanding term loan facility, prepaying a po</description>
</item>
</channel>
</rss>